<DOC>
	<DOCNO>NCT02819635</DOCNO>
	<brief_summary>This study comprise three sub-studies . The objective sub-study 1 characterize dose-response , efficacy , safety ABT-494 compare placebo induce clinical remission order identify induction dose ABT-494 evaluation sub-study 2 . The objective sub-study 2 evaluate efficacy safety ABT-494 compare placebo induce clinical remission participant . The objective sub-study 3 evaluate efficacy safety ABT-494 compare placebo achieve clinical remission participant response follow induction ABT-494 .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy ABT-494 Induction Maintenance Therapy Subjects With Moderately Severely Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Diagnosis ulcerative colitis 90 day great prior Baseline , confirm colonoscopy Screening Period , exclusion current infection , colonic dysplasia and/or malignancy . Appropriate documentation biopsy result consistent diagnosis UC , assessment Investigator , must available . Active ulcerative colitis Adapted Mayo score 5 9 point endoscopic sub score 2 3 ( confirmed central reader ) . Demonstrated inadequate response , loss response , intolerance corticosteroid , immunosuppressant , and/or biologic therapy . If female , participant must meet criterion Contraception Recommendations Pregnancy Testing . Female participant childbearing potential must negative serum pregnancy test Screening Visit negative urine pregnancy test Baseline Visit . Male participant must agree follow protocolspecified pregnancy avoidance measure , include refrain donate sperm , 90 day post last dose study drug . Participant current diagnosis Crohn 's disease ( CD ) diagnosis indeterminate colitis ( IC ) . Current diagnosis fulminant colitis and/or toxic megacolon . Participant disease limit rectum ( ulcerative proctitis ) Screening endoscopy . Received cyclosporine , tacrolimus , mycophenolate mofetil within 30 day prior Baseline . Participant azathioprine 6mercaptopurine within 10 day baseline . Received intravenous corticosteroid within 14 day prior Screening Screening Period . Participant previous exposure JAK inhibitor ( e.g. , tofacitinib , baricitinib , filgotinib ) . Screening laboratory analysis show abnormal result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ABT-494</keyword>
	<keyword>Moderately Severely Active UC</keyword>
</DOC>